Search

Your search keyword '"Pujadas, Sandra"' showing total 185 results
Start Over Author "Pujadas, Sandra"
185 results on '"Pujadas, Sandra"'

1. Design of the β3-Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure Trial

Author

Garcia-Lunar, Ines, Blanco, Isabel, Fernández-Friera, Leticia, Prat-Gonzàlez, Susanna, Jordà, Paloma, Sánchez, Javier, Pereda, Daniel, Pujadas, Sandra, Rivas-Lasarte, Mercedes, Solé-Gonzalez, Eduard, Vázquez, Jorge, Blázquez, Zorba, García-Picart, Juan, Caravaca, Pedro, Escalera, Noemí, Garcia-Pavia, Pablo, Delgado, Juan, Segovia-Cubero, Javier, Fuster, Valentín, Roig, Eulalia, Barberá, Joan Albert, Ibanez, Borja, and García-Álvarez, Ana

Published
2020
Full Text
View/download PDF

14. El conjunt arqueològic del segle XVI localitzat a la cisterna est del Castell de Montsoriu

Author

Tura, Jordi, Font. Gemma, Pujadas, Sandra, Mateu, Joaquim, and Llorens, Josep Maria

Subjects
Archaeology, Medieval, Arqueologia medieval, Urban archaeology, Arqueologia urbana, General Medicine
Abstract

From the second half of the 15th century, Montsoriu Castle began a slow and gradual process of decline that culminated in the abandonment of the castle, and the Viscounts of Cabrera and Bas selling the Viscounty to the Marquis of Aitona, in the last third of the 16th century. In this chronological context, we situate the discovery of one of the most outstanding closed archaeological assemblages located so far, corresponding to this period, and in a non-urban environment A partir de la segona meitat del s. x v, el castell de Montsoriu inicià un lent i progressiu procés de decadència que culminarà en l’abandonament del castell i venda del vescomtat per part dels vescomtes de Cabrera i Bas als Marquesos d’Aitona en el darrer terç del s. xvi. En aquest context cronològic s’emmarca la descoberta d’un dels conjunts arqueològics tancats més destacats que s’han localitzat fins ara corresponents aquest període i en un entorn no urbà

Published
2022

15. β3 adrenergic agonist treatment in chronic pulmonary hypertension associated with heart failure (SPHERE‐HF): a double blind, placebo‐controlled, randomized clinical trial.

Author

García‐Álvarez, Ana, Blanco, Isabel, García‐Lunar, Inés, Jordà, Paloma, Rodriguez‐Arias, Juan J., Fernández‐Friera, Leticia, Zegri, Isabel, Nuche, Jorge, Gomez‐Bueno, Manuel, Prat, Susanna, Pujadas, Sandra, Sole‐Gonzalez, Eduard, Garcia‐Cossio, Maria D., Rivas, Mercedes, Torrecilla, Estefanía, Pereda, Daniel, Sanchez, Javier, García‐Pavía, Pablo, Segovia‐Cubero, Javier, and Delgado, Juan F

Subjects
ADRENERGIC agonists, HEART failure, PULMONARY hypertension, CARDIAC magnetic resonance imaging, VENTRICULAR ejection fraction, CLINICAL trials, HEART diseases
Abstract

Aims: Pulmonary hypertension (PH) associated with left heart disease is an increasingly prevalent problem, orphan of targeted therapies, and related to a poor prognosis, particularly when pre‐ and post‐capillary PH combine. The current study aimed to determine whether treatment with the selective β3 adrenoreceptor agonist mirabegron improves outcomes in patients with combined pre‐ and post‐capillary PH (CpcPH). Methods and results: The β3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure (SPHERE‐HF) trial is a multicentre, randomized, parallel, placebo‐controlled clinical trial that enrolled stable patients with CpcPH associated with symptomatic heart failure. A total of 80 patients were assigned to receive mirabegron (50 mg daily, titrated till 200 mg daily, n = 39) or placebo (n = 41) for 16 weeks. Of them, 66 patients successfully completed the study protocol and were valid for the main analysis. The primary endpoint was the change in pulmonary vascular resistance (PVR) on right heart catheterization. Secondary outcomes included the change in right ventricular (RV) ejection fraction by cardiac magnetic resonance or computed tomography, other haemodynamic variables, functional class, and quality of life. The trial was negative for the primary outcome (placebo‐corrected mean difference of 0.62 Wood units, 95% confidence interval [CI] −0.38, 1.61, p = 0.218). Patients receiving mirabegron presented a significant improvement in RV ejection fraction as compared to placebo (placebo‐corrected mean difference of 3.0%, 95% CI 0.4, 5.7%, p = 0.026), without significant differences in other pre‐specified secondary outcomes. Conclusions: SPHERE‐HF is the first clinical trial to assess the potential benefit of β3 adrenergic agonists in PH. The trial was negative since mirabegron did not reduce PVR, the primary endpoint, in patients with CpcPH. On pre‐specified secondary outcomes, a significant improvement in RV ejection fraction assessed by advanced cardiac imaging was found, without differences in functional class or quality of life. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Differentiation of athlete's heart and hypertrophic cardiomyopathy by the fractal dimension of left ventricular trabeculae

Author

Vilades, David, primary, Garcia-Moll, Xavier, additional, Gomez-Llorente, Marta, additional, Pujadas, Sandra, additional, Ferrero-Gregori, Andreu, additional, Doñate, Teresa, additional, Mirabet, Sonia, additional, Leta, Ruben, additional, Pons-Lladó, Guillem, additional, Carreras, Francesc, additional, and Cinca, Juan, additional

Published
2021
Full Text
View/download PDF

35. Myocardial remodelling and tissue characterisation by cardiovascular magnetic resonance (CMR) in endurance athletes

Author

Pujadas, Sandra, Doñate, Maite, Li, Chi-Hion, Merchan, Soraya, Cabanillas, Ana, Alomar Serrallach, Xavier, Pons-Llado, Guillem, Serra-Grima, Ricard, Carreras Costa, Francesc, and Universitat Autònoma de Barcelona

Subjects
medicine.medical_specialty, Physical Therapy, Sports Therapy and Rehabilitation, heart, 030204 cardiovascular system & hematology, 030218 nuclear medicine & medical imaging, Running, 03 medical and health sciences, 0302 clinical medicine, Athlete, Internal medicine, Cardiopulmonary exercise test, running, medicine, Late gadolinium enhancement, Orthopedics and Sports Medicine, Myocardial mass, medicine.diagnostic_test, biology, business.industry, Athletes, Benignity, Magnetic resonance imaging, Heart, biology.organism_classification, radiology, Cardiology, Original Article, Myocardial fibrosis, athlete, business, Wall thickness, Radiology
Abstract

There is still some controversy about the benignity of structural changes observed in athlete’s heart, especially regarding the observation of increased biomarkers and the presence of myocardial fibrosis (MF).AimOur purpose was to evaluate by cardiovascular magnetic resonance (CMR) the presence of diffuse as well as focal MF in a series of high-performance veteran endurance athletes.MethodsThirty-four veteran healthy male endurance athletes, still being in regular training, with more than 10 years of training underwent a CMR. A cardiopulmonary exercise test was also performed to assess their maximal physical performance. The control group consisted in 12 non-trained normal individuals.ResultsWe found an increase in both, right and left ventricular (LV) volumes in the athlete’s group when compared with controls. There was no increase in indexed LV myocardial mass despite of a significantly increased maximal myocardial wall thickness in comparison to controls. Native T1 values and extracellular volume (ECV) were normal in all cases. We did not find differences in native T1 values and ECV between both groups. In three athletes (9%), non-ischaemic late gadolinium enhancement (LGE) was observed. We did not find a correlation between total training volume and presence of LGE or with the ECV value.ConclusionsOur results show that the majority of veteran endurance athletes present with myocardial remodelling without MF as a physiological adaptive phenomenon. In the only three athletes with focal MF, the LGE pattern observed suggests an intercurrent event not related with the remodelling phenomenon.

Published
2018

39. Misleading echocardiographic diagnosis of a prosthetic heart valve vegetation due to the cavitation phenomenon

Author

Arias, Ramón Suárez, Piñero-Uribe, Isabel, Carreras, Francesc, Pujadas, Sandra, Leta, Rubén, and Pons-Lladó, Guillem

Subjects
Clinical Cardiology: Case Report
Abstract

The cavitation phenomenon is caused by the local pressure depression that occurrs during the closure and/or opening of prosthetic valve leaflets. Occasionally, peculiar features of echocardiographic images generated by cavitation can simulate a mass or vegetation, and are a potential source of diagnostic error. A clinical case that illustrates this phenomenon is described.

Published
2009

42. TCT-206 Incidence and clinical impact of Side Branch Occlusion After Bioresorbable Vascular Scaffold Implantation for Chronic Total Occlusions: Insight from the CTO-ABSORB pilot study

Author

Vaquerizo, Beatriz, primary, Barros, Antonio, additional, Pujadas, Sandra, additional, Bajo, Ester, additional, ESTRADA-YÁNEZ, DARLENE, additional, Miranda-Guardiola, Faustino, additional, Jimenez, Marcelo, additional, Cinca, Juan, additional, and Serra, Antonio, additional

Published
2014
Full Text
View/download PDF

43. TCT-191 Health-related quality of life, Functional status and Myocardial ischemia in patients with successful chronic total occlusion recanalization

Author

Bajo, Ester, primary, Vaquerizo, Beatriz, additional, Pujadas, Sandra, additional, Rosello, Javier, additional, Barros, Antonio, additional, Miranda-Guardiola, Faustino, additional, Kockar, Marcelo Jimenez, additional, Carreras, Francesc, additional, Cinca, Juan, additional, and Serra, Antonio, additional

Published
2014
Full Text
View/download PDF

44. TCT-203 12-months Clinical Outcomes of Bioresorbable everolimus-eluting Vascular Scaffold for the Treatment of Chronic Total Occlusions: CTO ABSORB pilot study

Author

Vaquerizo, Beatriz, primary, Barros, Antonio, additional, Pujadas, Sandra, additional, Bajo, Ester, additional, ESTRADA-YÁNEZ, DARLENE, additional, Miranda-Guardiola, Faustino, additional, Jimenez, Marcelo, additional, Arzamendi, Dabit, additional, Garcia-Picart, Juan, additional, Cinca, Juan, additional, and Serra, Antonio, additional

Published
2014
Full Text
View/download PDF

45. TCT-218 Clinical benefit of Multi-detector computed tomography for percutaneous coronary intervention in Chronic Total Occlusions: TACCTO prospective randomized trial

Author

Vaquerizo, Beatriz, primary, Barros, Antonio, additional, Pujadas, Sandra, additional, Bajo, Ester, additional, ESTRADA-YÁNEZ, DARLENE, additional, Tizón, Helena, additional, Jimenez, Marcelo, additional, Miranda-Guardiola, Faustino, additional, Leta, Ruben, additional, Cinca, Juan, additional, and Serra, Antonio, additional

Published
2014
Full Text
View/download PDF

46. El Mas en el Montseny

Author

Estrada, Ferrán, Font, Gemma, Mateu, Joaquim, Pujadas, Sandra, Roigé, Xavier, and Tura, Jordi

Subjects
Viviendas, Arquitectura
Abstract

En número dedicado a: Barcelona

Published
2002

50. Determinantes del éxito de la revascularización de las oclusiones coronarias crónicas: estudio mediante tomografía computarizada con multidetectores

Author

Martín-Yuste, Victoria, primary, Barros, Antonio, additional, Leta, Ruben, additional, Ferreira, Ignacio, additional, Brugaletta, Salvatore, additional, Pujadas, Sandra, additional, Carreras, Francesc, additional, Pons, Guillem, additional, Cinca, Joan, additional, and Sabate, Manel, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results